On Friday, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was 11.88% up from the session before settling in for the closing price of $0.77. A 52-week range for LXRX has been $0.76 – $3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 186.21%. When this article was written, the company’s average yearly earnings per share was at 16.20%. With a float of $304.81 million, this company’s outstanding shares have now reached $361.49 million.
Let’s determine the extent of company efficiency that accounts for 285 employees. In terms of profitability, gross margin is 87.97%, operating margin of -4037.43%, and the pretax margin is -4109.41%.
Lexicon Pharmaceuticals Inc (LXRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lexicon Pharmaceuticals Inc stocks. The insider ownership of Lexicon Pharmaceuticals Inc is 15.68%, while institutional ownership is 67.30%. The most recent insider transaction that took place on Aug 15 ’24, was worth 480,000.
Lexicon Pharmaceuticals Inc (LXRX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.2 earnings per share (EPS) during the time that was better than consensus figure (set at -0.23) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.20% per share during the next fiscal year.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Trading Performance Indicators
You can see what Lexicon Pharmaceuticals Inc (LXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 66.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.42 in one year’s time.
Technical Analysis of Lexicon Pharmaceuticals Inc (LXRX)
Looking closely at Lexicon Pharmaceuticals Inc (NASDAQ: LXRX), its last 5-days average volume was 4.55 million, which is a jump from its year-to-date volume of 3.51 million. As of the previous 9 days, the stock’s Stochastic %D was 9.74%. Additionally, its Average True Range was 0.13.
During the past 100 days, Lexicon Pharmaceuticals Inc’s (LXRX) raw stochastic average was set at 7.76%, which indicates a significant decrease from 21.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.14% in the past 14 days, which was lower than the 109.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5248, while its 200-day Moving Average is $1.8592. However, in the short run, Lexicon Pharmaceuticals Inc’s stock first resistance to watch stands at $0.9257. Second resistance stands at $0.9881. The third major resistance level sits at $1.0859. If the price goes on to break the first support level at $0.7655, it is likely to go to the next support level at $0.6677. Should the price break the second support level, the third support level stands at $0.6053.
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Key Stats
There are 246,237K outstanding shares of the company, which has a market capitalization of 349.20 million. As of now, sales total 1,200 K while income totals -177,120 K. Its latest quarter income was 1,750 K while its last quarter net income were -64,810 K.
